Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 18/20 | 0.81 |
| ▸ | KIT | P10721 | 17/20 | 0.81 |
| ▸ | SRC | P12931 | 16/20 | 0.81 |
| ▸ | KDR | P35968 | 8/20 | 0.75 |
| ▸ | ABL1 | P00519 | 1/20 | 0.70 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.70 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256148 | 0.92 | LCK (0.88) | LCKKITSRCKDRABL1 | |
| SCHEMBL3250978 | 0.90 | LCK (1.00) | LCKKITSRCKDRABL1 | |
| SCHEMBL3249502 | 0.89 | LCK (0.82) | LCKKITSRCKDRABL1 | |
| SCHEMBL3254427 | 0.88 | LCK (0.81) | LCKKITSRCKDRABL1 | |
| SCHEMBL3249706 | 0.88 | LCK (1.00) | LCKKITSRCKDRABL1 | |
| SCHEMBL3249849 | 0.87 | LCK (0.82) | LCKKITSRCKDRABL1 | |
| SCHEMBL3252037 | 0.86 | LCK (0.88) | LCKKITSRCKDRABL1 | |
| SCHEMBL3248124 | 0.86 | LCK (0.83) | LCKKITSRCKDRABL1 | |
| SCHEMBL3258113 | 0.86 | LCK (0.81) | LCKKITSRCKDRABL1 | |
| SCHEMBL1345616 | 0.86 | LCK (0.81) | LCKKITSRCKDRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079724-B1 | SUBSTITUTED PYRIDONE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2010-05-26 | — | — | EP | claimed |
| US-7700607-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2010-04-20 | — | — | US | claimed |
| EP-2079724-A2 | SUBSTITUTED PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2009-07-22 | — | — | EP | claimed |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2008-10-09 | — | — | US | claimed |
| WO-2008011109-A2 | SUBSTITUTED PYRIDONE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2008-01-24 | — | — | WO | claimed |
| EP-2079724-B1 | SUBSTITUTED PYRIDONE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2010-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | KIT, CMA1, C3AR1 | LCK 323/4885KIT 1/4885SRC 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.